NYSE:CVM CEL-SCI (CVM) Stock Price, News & Analysis $2.50 -0.01 (-0.40%) Closing price 04:00 PM EasternExtended Trading$2.47 -0.03 (-1.24%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About CEL-SCI Stock (NYSE:CVM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CEL-SCI alerts:Sign Up Key Stats Today's Range$2.35▼$2.5450-Day Range$2.46▼$9.1852-Week Range$2.32▼$66.60Volume280,124 shsAverage Volume52,995 shsMarket Capitalization$7.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Read More… Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter. Email Address CVM Stock News HeadlinesCEL-SCI Announces Closing of Public OfferingMay 23, 2025 | businesswire.comBiggest stock movers Thursday: SNOW, URBN, and moreMay 22, 2025 | msn.comTrump Makes Major Crypto AnnouncementYou Won’t Get a Second Chance at This Entry The crypto comeback isn't coming—it's already here. And one particular coin is sitting right at the center of this shift.May 28, 2025 | Crypto 101 Media (Ad)CEL-SCI plummets 44%, prices $5M stock offeringMay 22, 2025 | msn.comCEL-SCI Announces Pricing of Public OfferingMay 21, 2025 | businesswire.comCEL-SCI Implements 1-for-30 Stock Split To Support Share PriceMay 21, 2025 | nasdaq.comCEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi ArabiaMay 21, 2025 | finance.yahoo.comCEL-SCI Announces Proposed Public OfferingMay 21, 2025 | businesswire.comSee More Headlines CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed this year? CEL-SCI's stock was trading at $11.9970 at the beginning of 2025. Since then, CVM shares have decreased by 79.2% and is now trading at $2.50. View the best growth stocks for 2025 here. How were CEL-SCI's earnings last quarter? CEL-SCI Co. (NYSE:CVM) announced its earnings results on Thursday, August, 15th. The company reported ($4.20) EPS for the quarter, missing analysts' consensus estimates of ($3.90) by $0.30. When did CEL-SCI's stock split? CEL-SCI's stock reverse split on the morning of Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are CEL-SCI's major shareholders? Top institutional shareholders of CEL-SCI include MAI Capital Management (0.63%). Insiders that own company stock include Geert R Kersten, Patricia B Prichep and Robert Eugene Watson. View institutional ownership trends. How do I buy shares of CEL-SCI? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CEL-SCI own? Based on aggregate information from My MarketBeat watchlists, some other companies that CEL-SCI investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Pfizer (PFE), Canopy Growth (CGC) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/15/2024Today5/28/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:CVM CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471Employees43Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($12.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-238.05% Return on Assets-104.65% Debt Debt-to-Equity Ratio0.66 Current Ratio1.07 Quick Ratio1.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book16.47Miscellaneous Outstanding Shares3,032,000Free Float64,673,000Market Cap$7.49 million OptionableOptionable Beta0.50 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NYSE:CVM) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.